February 2022 - Page 13 of 26

TuesdayFeb 15, 2022 1:19 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), The Chopra Foundation Partner to Uncover Potential of Psychedelic Therapies in Mental Health

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has entered a strategic partnership with The Chopra Foundation, a not-for-profit organization founded by Dr. Deepak Chopra, dedicated to improving health and well-being. Under the collaboration, The Chopra Foundation is working closely with Cybin to support education and awareness about its groundbreaking research to harness the potential of psychedelic therapies in mental health. Emerging research shows the potential for psychedelic-assisted therapy to improve the quality of life for people suffering with mental illnesses, including those specific indications that Cybin is targeting, such as major depressive…

TuesdayFeb 15, 2022 12:46 pm

QualityStocksNewsBreaks – Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Closes Strategic Investment, Setting Stage for International Growth, Further Collaboration

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) today announced that it has closed a strategic investment from Nurture Healthy Food LLP, a wholly owned subsidiary of Nurture Capital LLC, on a non-brokered private placement basis for gross proceeds of $5,017,999.50. Per the strategic investment, the company issued 6,690,666 units, each at a price of $0.75, with each unit comprised of one common share of the company and one half of one common share purchase warrant at an exercise price of $1.00 per share, exercisable for 36 months after closing of the offering. “Our partnerships form an integral component of…

TuesdayFeb 15, 2022 12:31 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has appointed Gerard (Jerry) P. Griffin III as vice president of sales and marketing at BayMedica, a wholly owned subsidiary of InMed. In his new role, Griffin will manage the commercialization of BayMedica’s health and wellness business including existing products as well as the launch of new products. Griffin brings a rich background to this position, having a proven track record as a veteran sales executive. He has served in several senior positions in Fortune 500 companies, including most recently as VP of sales…

TuesdayFeb 15, 2022 11:04 am

QualityStocksNewsBreaks – Kronos Advanced Technologies Inc.’s (KNOS) Patent Pending Graphene Masks Provide Superior Efficacy with 99.9% Viral and Bacterial Filtration

Kronos Advanced Technologies (OTC: KNOS), a revenue-generating product development and production company that has significantly changed the way air is moved, filtered and disinfected, today announced test results from Nelson Labs demonstrating significantly enhanced bacterial filtration efficiency (“BFE”) and viral filtration efficiency (“VFE”). According to the update, Kronos' designed and U.S. manufactured 5-ply graphene face masks remove 99.9% of bacteria and virus particles compared to the common and far less efficacious ASTM level 3 mask. The company believes that, with BFE and VFE levels over 99.9%, these are the highest filtration efficiency numbers for any face masks in the market.…

TuesdayFeb 15, 2022 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addiction Mydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment options The license allows Mydecine to provide psilocybin and MDMA (Ecstasy) through its licensed Alberta facility and collaboration with non-profit drug development institute Applied Pharmaceutical Innovation The company has named pharmaceutical scientist and entrepreneur Dr. Victoria Hale to its Board of Directors, strengthening…

TuesdayFeb 15, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing the Conversation on Psychedelics and Access to Psychedelic Treatments for Persons Living with Mental Health Conditions

Delic seeks to bring mental health treatment closer to the people through an aggressive expansion plan In a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made available Studies such as these are helping Delic drive the conversation on psychedelics forward The company seeks to take this conversation further with its participation at this year’s Emerald Conference Over 51.5 million people have experienced a mental health condition in the United States alone, with the figures rising owing to the…

TuesdayFeb 15, 2022 9:00 am

Building Value for Companies and Investors: SRAX Inc. (NASDAQ: SRAX) Buys Back Stock, Pays Dividend

SRAX has published a replay of its recent 2022 Sequire Metals & Mining Conference, including keynotes, and presentations from 70+ premier companies Per the $10 million share repurchase plan announced in Q3 2021, SRAX repurchased approximately $800,000 worth of stock during Q4 The company also made its first dividend payment through the delivery of preferred stock to shareholders Most companies use technology to build value for themselves. SRAX (NASDAQ: SRAX) has taken it to a different level, using its technology to build corporate value by showcasing the opportunities in other companies. The Los Angeles-based company operates a portfolio of investor…

MondayFeb 14, 2022 2:22 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies

InMed Pharmaceuticals (NASDAQ: INM) understands the immense potential of rare cannabinoids and sees them as having applications as wide as cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), variants of cannabinoids that make up most of the content in cannabis plants. Studies suggest that rare cannabinoids could offer more potent medical benefits than CBD and without the psychoactive attribute of THC, representing a huge market. “However, the industry wide problem has always been to obtain the production scales necessary for cost-effective commercialization of such compounds, while also ensuring the purity and consistency that can be difficult at even low volumes. The answer is…

MondayFeb 14, 2022 2:04 pm

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Furthering Global Foothold as Leader in Plant-Based Wellness, Lifestyle Brands

Flora Growth Corp. (NASDAQ: FLGC) is expanding its cannabis-derived brand presence in Latin American countries. Its Mind Naturals skincare brand, built with premium CBD and other high-quality ingredients, will be distributing a portfolio of 12 products through its agreement with Walmart’s online marketplace and Coppel e-commerce outlets. Walmart and Coppel are leading retail chains in Mexico and Central America. A recent article quotes Flora Growth CEO Luis Merchan as saying, “This agreement represents our first foray into the Mexican market and furthers our global foothold as a leader in plant-based wellness and lifestyle brands… As the cannabis market continues its…

MondayFeb 14, 2022 1:51 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Working on Turning Psychedelics-to-Therapeutics(TM) Vision into Reality

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is on a mission to revolutionize mental health care. The company has developed key relationships with a network of world-class partners and internationally recognized scientists as it focuses on creating safe and effective therapeutics for patients to address a multitude of mental health issues. “The company is working on turning its Psychedelics to Therapeutics(TM) vision into reality by engineering drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders,” reads a recent article, which contains excerpts…

Site Search

Company Search

Month: February 2022